Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
42 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Redhill Biopharma Ltd.’s names, not what it holds today.
Patents granted
42
41 utility, 1 design, 1976 to Dec 31, 2025
Granted in 2025
2
Against 4 in 2024 and 3 in 2023
Applications published
48
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
RedHill Biopharma Ltd. its own name
IL, as the owner printed on each patent
42 granted
8 publishedRedHill Biopharma Ltd. its own name
named as the applicant on its applications, in IL
0 granted
40 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Dec 23, 2025 | 12,502,381 | Serine protease inhibitor for treating coronavirus infection | Pharmaceuticals | RedHill Biopharma Ltd. |
| Jul 29, 2025 | 12,370,206 | Therapy for inhibition of single-stranded RNA virus replication | Pharmaceuticals | RedHill Biopharma Ltd. |
| Oct 15, 2024 | 12,115,150 | Biomarkers of coronavirus pneumonia | Pharmaceuticals | RedHill Biopharma Ltd. |
| Mar 19, 2024 | 11,931,463 | All-in-one fixed-dose combination for treating Helicobacter pylori infection | Pharmaceuticals | RedHill Biopharma Ltd. |
| Mar 5, 2024 | 11,918,560 | Serine protease inhibitor for treating coronavirus infection | Pharmaceuticals | RedHill Biopharma Ltd. |
| Jan 23, 2024 | 11,878,011 | Method for eradicating Helicobacter pylori infection in patients regardless of body mass index | Pharmaceuticals | RedHill Biopharma Ltd. |
| Oct 17, 2023 | 11,786,541 | Inhibitor of sphingosine kinase 2 for treating Ebola | Pharmaceuticals | RedHill Biopharma Ltd. |
| Apr 25, 2023 | 11,633,385 | Combination compositions for treatment of cancer | Pharmaceuticals | RedHill Biopharma Ltd. |
| Feb 28, 2023 | 11,590,154 | Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections | Pharmaceuticals | RedHill Biopharma Ltd. |
| Oct 18, 2022 | 11,471,448 | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia | Pharmaceuticals | RedHill Biopharma Ltd. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 23, 2025 | 2025/0325577 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | Pharmaceuticals | RedHill Biopharma Ltd. |
| Oct 24, 2024 | 2024/0350461 | SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTION | Pharmaceuticals | RedHill Biopharma Ltd. · patent 12,502,381 granted from it |
| Oct 3, 2024 | 2024/0325313 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI | Pharmaceuticals | RedHill Biopharma Ltd. |
| Apr 4, 2024 | 2024/0108643 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | Pharmaceuticals | RedHill Biopharma Ltd. · patent 12,370,206 granted from it |
| Mar 28, 2024 | 2024/0100034 | METHOD FOR ERADICATING HELICOBACTER PYLORI INFECTION IN PATIENTS REGARDLESS OF BODY MASS INDEX | Pharmaceuticals | RedHill Biopharma Ltd. |
| Jan 5, 2023 | 2023/0000845 | BIOMARKERS OF CORONAVIRUS PNEUMONIA | Pharmaceuticals | RedHill Biopharma Ltd. · patent 12,115,150 granted from it |
| Jun 16, 2022 | 2022/0184053 | SPHINGOSINE KINASE 2 INHIBITOR FOR TREATING CORONAVIRUS INFECTION IN MODERATELY SEVERE PATIENTS WITH PNEUMONIA | Pharmaceuticals | RedHill Biopharma Ltd. · patent 11,471,448 granted from it |
| Mar 3, 2022 | 2022/0062188 | ALL-IN-ONE FIXED-DOSE COMBINATION FOR TREATING HELICOBACTER PYLORI INFECTION | Pharmaceuticals | RedHill Biopharma Ltd. · patent 11,931,463 granted from it |
| Feb 3, 2022 | 2022/0031682 | SPHINGOSINE KINASE 2 INHIBITOR FOR TREATING CORONAVIRUS INFECTION | Pharmaceuticals | RedHill Biopharma Ltd. · patent 11,364,227 granted from it |
| Dec 30, 2021 | 2021/0401865 | TRIPLE ANTIBIOTIC FIXED-DOSE COMBINATION PRODUCTS, DOSING REGIMEN, METHODS, AND KITS FOR TREATING PULMONARY NON-TUBERCULOSIS MYCOBACTERIAL INFECTIONS | Pharmaceuticals | RedHill Biopharma Ltd. · patent 11,590,154 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 5.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.